Ranbaxy’s Troubles Continue – WHO Plans “Extra-ordinary” Action To Confirm Safety Of Prequalified Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The cascading effect of U.S. FDA's enforcement action against India's largest drug maker Ranbaxy has reached the World Health Organization. On its website, WHO has observed that several inspections of Ranbaxy's Paonta Sahib site - most recently in June 2008 - revealed noncompliance with WHO good manufacturing practices standards